Vitiligo is an acquired depigmentation disorder with exact etiology is not yet known. Autoimmune hypothesis plays an important role in the mechanism of vitiligo and has been related to lower levels of 25-hydroxyvitamin D (25-(OH)D). This study aimed to analyze the comparison effect of combination therapy of NB-UVB phototherapy and vitamin D 3 supplement toward NB-UVB phototherapy alone to increase of serum 25-(OH)D levels in vitiligo patients. Subjects consisted of 24 adult vitiligo patients: group I was given a combination of NB-UVB phototherapy and 5000 IU vitamin D 3 once daily; while group II was given monotherapy of NB-UVB. There was a very significant increase of serum 25-(OH)D level in group I with an average increase was 288.65%, while group II showed a significant increase of serum 25-(OH)D serum with an average increase was 33.63%. The very significant result was seen between both groups. None of the subjects showed signs of vitamin D toxicities during treatment. The study concluded that combination of NB-UVB phototherapy and vitamin D 3 supplementation gave a better effect to increase of serum 25-(OH)D levels in adult vitiligo patients.
Introduction
Vitiligo is a skin disorder characterized by depigmentation macules caused by selective loss of melanocytes, with varying responses to therapies. 1 The pathogenesis of vitiligo is complex with interaction of multiple factors, however, the exact mechanism is not yet known. 2 The autoimmune mediated destruction of melanocytes is well accepted and has been the most prominent hypothesis in vitiligo pathogenesis. The immune reactions can be mediated by cellular immunity, humoral immunity, and action of cytokines. 3 Vitiligo has been related with reduced vitamin D levels. Deficiency of vitamin D was suggested as a trigger for autoimmunity, 4 therefore the supplementation of vitamin D can probably be used as a treatment for vitiligo. 5 The synthesis of vitamin D occurs in epidermis from the precursor molecule 7-dehydrocholesterol (provitamin D 3 ) to previtamin D 3 by ultraviolet B (UVB) radiation. Previtamin D 3 next converted into vitamin D 3 (cholecalciferol) through spontaneous, temperature-dependent isomerization. Once in the circulation, vitamin D is transformed into 25-hydroxyvitamin D (25-(OH)D) by hepatic hydroxylase enzyme. 6 The circulating 25-(OH)D level is an indicator of the vitamin D status, 7 which is the best available clinical marker for diagnosis of vitamin D deficiency. 8 According to Beheshti et al., 9 serum vitamin D level in patients with autoimmune disease should be assessed, and if there is a lack, the patients should be treated. Vitamin D intake and effective sun exposure are the major determinants of the serum 25-(OH)D level. 6, 8 The Phototherapy is one of the best known and documented treatment options in vitiligo. Narrowband ultraviolet (NB-UVB) has been the effective and safe therapy for vitiligo. 10 Previous study showed that vitiligo patients receiving NB-UVB phototherapy had increase in serum 25-(OH)D levels. 11 However, based on our knowledge, there still no data about the influence of vitamin D supplementation on NB-UVB phototherapy as a long-known proven treatment in vitiligo.
According to the previous studies above, we aimed to analyze the advantages of combination treatment of NB-UVB phototherapy and oral vitamin D 3 5000 IU compared to NB-UVB phototherapy alone to increase serum 25-(OH)D levels in adult vitiligo patients.
Materials and Methods
This study was an analytical, prospective, experimental study with blocked randomized controlled trial. The subjects con- 
Results
This study included 24 adult vitiligo patients, consisted of 10 males (41.7%) and 14 females (58.3%). Most patients in our study were adults, with range of age were 25-64 years old, and most patients had history of topical therapy (45.8%). The characteristics of subjects are shown in Table 1 .
The mean 25-(OH)D level before therapy in group I was 11.29±4.500 ng/ml, while in group II was 13.04±4.830 ng/ml. After treatment there was a very significant increase of serum 25-(OH)D level in group I by mean level was 37.88±9.958 ng/ml with average increase was 288.65% (p = 0.001) ( Table 2 ). 10 of 13 subjects (76.92%) had normal serum 25-(OH)D after treatment. Group II showed significant increase of 25-(OH)D serum by mean level was 16.26±4.899 ng/ml with average increase was 33.63% (p < 0.05) ( Table 2 ), but no subject had normal 25-(OH)D after treatment. Interestingly, three patients in group II had decrement of serum 25-(OH)D levels after receiving phototherapy. Very significant result (p = 0.000*) was seen in comparison of average increase of serum 25-(OH)D levels between both groups (Table  3) . None of subjects showed symptoms of vitamin D toxicities during treatment.
Discussion
Our data showed that combination treatment of NB-UVB phototherapy and vitamin D 3 supplement gave a better effect than monotherapy of NB-UVB phototherapy to increase serum 25-(OH)D levels in adult vitiligo patients. The previous study by Sehrawat et al. 4 revealed that serum (25-(OH)D) levels increased in vitiligo patients after 12 weeks of NB-UVB treatment with moderate correlation. They also found that serum 25-(OH)D levels increased significantly with increase in the cumulative dose of NB-UVB. Our data also showed significant improvement of serum 25-(OH)D levels after receiving NB-UVB phototherapy for eight weeks. To the best of our knowledge, this was the first study examining the comparison effect of combination therapy of NB-UVB phototherapy and vitamin D 3 supplementation toward NB-UVB phototherapy alone to increase serum 25-(OH)D levels in adult vitiligo patients. Similar study was done by Ala-Houhala et al. 12 that gave NB-UVB treatment in 12 psoriasis patients who were supplemented with oral cholecalciferol 20 µg daily. They found that NB-UVB treatment significantly increased serum 25-(OH)D level in patients with psoriasis who were taking oral vitamin D supplementation, with concentration of serum 25-(OH)D remained below the toxicity level. Meanwhile, Finamor et al. 13 in their previous study showed that oral vitamin D 3 35,000 IU once daily for six month could significantly increase vitamin D levels in vitiligo patients. We gave oral vitamin D 3 5000 IU in our study based on the recommendations for management of vitamin D deficiency that high dosage of vitamin D as 3000-5000 IU daily for 6-12 weeks can 4 However, sun exposure and daily activities were not controlled in our study, consequently became this study limitations.
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Conclusions
Combination treatment of NB-UVB phototherapy and vitamin D 3 supplement gave better effect than phototherapy alone to increase serum 25-(OH)D levels in adult vitiligo patients.
